ATE349511T1 - Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten - Google Patents
Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthaltenInfo
- Publication number
- ATE349511T1 ATE349511T1 AT01908427T AT01908427T ATE349511T1 AT E349511 T1 ATE349511 T1 AT E349511T1 AT 01908427 T AT01908427 T AT 01908427T AT 01908427 T AT01908427 T AT 01908427T AT E349511 T1 ATE349511 T1 AT E349511T1
- Authority
- AT
- Austria
- Prior art keywords
- microorganisms
- obesity
- prevention
- treatment
- diabetes mellitus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/02—Acetobacter
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/823—Acetobacter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20000026379 | 2000-05-17 | ||
KR10-2000-0049805A KR100404236B1 (ko) | 2000-05-17 | 2000-08-26 | 비만 또는 당뇨병 치료용 미생물 및 상기 미생물을포함하는 의약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE349511T1 true ATE349511T1 (de) | 2007-01-15 |
Family
ID=26637996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01908427T ATE349511T1 (de) | 2000-05-17 | 2001-02-23 | Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten |
Country Status (8)
Country | Link |
---|---|
US (4) | US6808703B2 (de) |
EP (1) | EP1282687B1 (de) |
JP (1) | JP4580542B2 (de) |
CN (1) | CN1380902B (de) |
AT (1) | ATE349511T1 (de) |
AU (1) | AU3617001A (de) |
DE (1) | DE60125529T2 (de) |
WO (1) | WO2001088095A1 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1533430A (zh) * | 2000-12-21 | 2004-09-29 | �Ʒ� | 能生产果聚糖的乳杆菌属菌株及其在人类或宠物食品中的用途 |
US6942857B2 (en) * | 2002-08-09 | 2005-09-13 | Bioneer Corporation | Microorganisms for preventing and/or treating obesity or diabetes mellitus |
PT1545562E (pt) * | 2002-09-09 | 2006-09-29 | Nl Organizatie Voor Toegepast | Alfa-glucanos ramificados para o controlo de peso |
EP1639108A2 (de) | 2003-02-28 | 2006-03-29 | McGILL UNIVERSITY | Zellen und enzyme enthaltende zusammensetzungen zur regulierung von gallensäuren, cholesterol und triglyceriden |
MX2007009659A (es) * | 2005-02-11 | 2008-01-16 | Technologie Biolactis Inc | Uso de lactobacillus kefiranofaciens en la forma de un probiotico y un simbiotico. |
US20100216212A1 (en) * | 2005-07-26 | 2010-08-26 | School Corp., Azabu Veterin Med. Educa'l Institu | Anti-obesity agent and anti-obesity food |
SE529185C2 (sv) * | 2005-10-07 | 2007-05-22 | Arla Foods Amba | Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt |
EP1983849B1 (de) * | 2006-01-20 | 2013-04-03 | Innova Food AB | Aminosäurehaltige nahrungsmittelzusammensetzung |
PL1981516T3 (pl) | 2006-01-27 | 2019-03-29 | Dupont Nutrition Biosciences Aps | Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom |
EP2046943B1 (de) * | 2006-08-04 | 2013-06-19 | Bioneer Corporation | Aus muttermilch isolierte milchsäurebakterien mit probiotischer aktivität und hemmaktivität gegen körpergewichtszunahme |
JP5089942B2 (ja) * | 2006-09-04 | 2012-12-05 | 雪印メグミルク株式会社 | 内臓脂肪蓄積抑制剤 |
CN101678051B (zh) * | 2006-09-04 | 2012-12-12 | 雪印惠乳业株式会社 | 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂 |
EP2073643A2 (de) * | 2006-10-18 | 2009-07-01 | DSMIP Assets B.V. | Verkapselung von hitze- und feuchtigkeitsempfindlichen substanzen |
EP1987726A1 (de) * | 2007-05-01 | 2008-11-05 | Friesland Brands B.V. | Wohlschmeckendes Nahrungsmittel mit Neutralisierungsmittel für Verbindungen mit Nebenwirkungen |
EP2011506A1 (de) | 2007-07-05 | 2009-01-07 | Nestec S.A. | Ergänzung zu einer Schwangerschaftsdiät |
JP2009114163A (ja) * | 2007-11-05 | 2009-05-28 | Nippon Energy Kenkyusho:Kk | 複合微生物の培養生成物を有効成分とする血糖降下剤および血糖降下機能食品 |
MX2010005453A (es) * | 2007-11-19 | 2010-08-31 | Kaneka Corp | Preparacion que contiene bacteria de acido lactico. |
EP2065048A1 (de) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung |
EP2262514B8 (de) * | 2008-03-07 | 2019-12-18 | Megmilk Snow Brand Co., Ltd. | Mittel zur förderung der sekretion und/oder unterdrückung der abnahme von adiponectin |
DK2100604T3 (da) * | 2008-03-10 | 2012-07-23 | Nestec Sa | Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser |
US20110189149A1 (en) * | 2008-06-20 | 2011-08-04 | Remy Burcelin | New Uses of Lactic Acid Bacteria and Bifidobacteria |
US9474773B2 (en) | 2009-02-18 | 2016-10-25 | University Of Florida Research Foundation, Inc. | Lactobacillus supplement for alleviating type 1 diabetes |
JP5569710B2 (ja) * | 2009-02-27 | 2014-08-13 | 国立大学法人広島大学 | 肥満予防又は改善剤 |
US8986675B2 (en) * | 2009-03-10 | 2015-03-24 | Jinis Biopharmaceuticals Co. | Compositions and methods for prevention and treatment of obesity and obesity related metabolic syndrome |
EP2808024B1 (de) * | 2009-06-19 | 2019-04-24 | DuPont Nutrition Biosciences ApS | Bifidobakterien zur Behandlung von kongestiver herzinsuffizienz |
CN101703528B (zh) * | 2009-11-25 | 2012-07-04 | 王立平 | 一种治疗糖尿病的复合微生物制剂及其制备方法和应用 |
CN102935092B (zh) * | 2010-06-09 | 2014-03-26 | 景岳生物科技股份有限公司 | 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用 |
ES2389547B1 (es) * | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
KR101234582B1 (ko) * | 2011-04-22 | 2013-02-19 | 전남대학교산학협력단 | 알파 글루코시다제 활성 저해용 조성물 |
KR101228035B1 (ko) * | 2011-06-29 | 2013-01-30 | 주식회사 쎌바이오텍 | 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물 |
CN102533588B (zh) * | 2011-12-06 | 2013-12-11 | 光明乳业股份有限公司 | 一株产胞外多糖的短乳杆菌及其应用 |
EP2836224A4 (de) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | Zusammensetzungen von biozönose und zugehörige verfahren |
JP5967527B2 (ja) * | 2012-06-22 | 2016-08-10 | 国立研究開発法人産業技術総合研究所 | 食欲増進かつ体重増加抑制剤 |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
CA3092318A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
US9603880B2 (en) | 2013-04-17 | 2017-03-28 | Suntory Holdings Limited | Composition containing bacterium belonging to genus lactobacillus |
CN103275905B (zh) * | 2013-05-31 | 2014-12-10 | 江南大学 | 具有预防糖尿病作用的鼠李糖乳杆菌ccfm0528 |
CN105407728A (zh) | 2013-07-21 | 2016-03-16 | 霍勒拜欧姆公司 | 用于微生物组表征、监测和治疗的方法和系统 |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
EP3050023B1 (de) | 2014-10-27 | 2021-08-25 | Aseko, Inc. | Subkutane ambulante verwaltung |
WO2016070151A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome. Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
GB2553701A (en) * | 2015-03-18 | 2018-03-14 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
US20160353774A1 (en) * | 2015-06-02 | 2016-12-08 | Mead Johnson Nutrition Company | Nutritional compositions comprising spore-forming probiotics |
JP6858751B2 (ja) | 2015-08-20 | 2021-04-14 | アセコー インコーポレイテッド | 糖尿病管理療法アドバイザ |
CN107028985A (zh) * | 2016-02-04 | 2017-08-11 | 深圳华大基因研究院 | 厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用 |
JP6785509B2 (ja) * | 2016-02-24 | 2020-11-18 | Noster株式会社 | ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物 |
US10653728B2 (en) | 2016-10-17 | 2020-05-19 | New York University | Probiotic compositions for improving metabolism and immunity |
CA3046705A1 (en) | 2017-02-10 | 2018-08-16 | Perfect (China) Co., Ltd. | Novel probiotics bifidobacteria strains |
US11389487B2 (en) | 2017-08-06 | 2022-07-19 | Second Genome, Inc. | Streptococcus australis as a biotherapeutic |
JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス, インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
EP3688196A4 (de) | 2017-09-26 | 2021-07-14 | Second Genome, Inc. | Gemella sanguinis als biotherapeutika |
TWI710321B (zh) * | 2018-05-03 | 2020-11-21 | 綠茵生技股份有限公司 | 低糖蔬果酵素液之製作方法 |
JP7219026B2 (ja) * | 2018-07-11 | 2023-02-07 | 雪印メグミルク株式会社 | 食後血糖値上昇抑制用組成物及びその製造方法 |
JP7267020B2 (ja) * | 2019-01-24 | 2023-05-01 | 株式会社明治 | 血糖値上昇抑制作用を有する発酵乳 |
WO2020175869A2 (ko) * | 2019-02-26 | 2020-09-03 | 전남대학교산학협력단 | 신규한 락토바실러스 사케이 cvl-001 균주 또는 이의 배양액을 포함하는 골 질환 또는 대사성 질환 개선, 예방 또는 치료용 조성물 |
CN110184214B (zh) * | 2019-05-21 | 2022-07-01 | 黑龙江大学 | 一种开菲尔乳杆菌及其菌制剂 |
CN110144311B (zh) * | 2019-05-21 | 2022-07-01 | 黑龙江大学 | 一种开菲尔乳杆菌及其菌制剂 |
CN111587952A (zh) * | 2020-05-27 | 2020-08-28 | 佛山科学技术学院 | 一种降低家犬体脂沉积的益生菌添加剂 |
CN111661933B (zh) * | 2020-06-30 | 2022-08-16 | 武汉合缘绿色生物股份有限公司 | 一种用于调节水体营养及预防病害的生物制剂及其制备方法 |
CN113512520B (zh) * | 2021-04-29 | 2022-04-26 | 右江民族医学院 | 富铬富锌醋酸杆菌及其制备方法和应用 |
EP4183403A1 (de) * | 2021-11-19 | 2023-05-24 | Lietuvos Sveikatos Mokslu Universitetas | Modifikation von fäkalen mikrobiota mit kapseln, die gram-positive bakterien enthalten |
CN116121154B (zh) * | 2023-04-10 | 2023-06-27 | 四川厌氧生物科技有限责任公司 | 一种乳明串珠菌及其应用 |
CN117925484A (zh) * | 2024-03-19 | 2024-04-26 | 山东中科嘉亿生物工程有限公司 | 一株改善睡眠呼吸暂停的罗伊氏粘液乳杆菌jylb-101及其产品和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0075604A1 (de) * | 1981-09-24 | 1983-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Mittel zur Senkung des Blutzuckerspiegels |
US4568557A (en) * | 1983-05-11 | 1986-02-04 | Warner-Lambert Company | Process for producing snack food product with high dietary fiber content |
JPS615019A (ja) * | 1984-06-18 | 1986-01-10 | Nakano Vinegar Co Ltd | 血糖低下剤 |
EP0194794A3 (de) * | 1985-03-08 | 1986-12-17 | Takeda Chemical Industries, Ltd. | Saccharid-Verdauung hemmende Zusammensetzung |
US5527772A (en) * | 1987-10-20 | 1996-06-18 | Holick; Michael F. | Regulation of cell proliferation and differentiation using peptides |
JP2928335B2 (ja) * | 1989-06-26 | 1999-08-03 | 株式会社ヤクルト本社 | 抗高血圧剤および飲食品 |
JP2939491B2 (ja) * | 1989-12-11 | 1999-08-25 | 株式会社アドバンス | 機能性食品 |
JPH0735339B2 (ja) * | 1991-09-09 | 1995-04-19 | 雪印乳業株式会社 | 血清コレステロール上昇抑制剤及び飲食品 |
JP3187502B2 (ja) * | 1992-01-09 | 2001-07-11 | カネボウ株式会社 | 腸溶性造粒物 |
JP3202053B2 (ja) * | 1992-01-09 | 2001-08-27 | カネボウ株式会社 | 腸溶性造粒物 |
CA2127392C (en) * | 1993-07-08 | 2008-05-27 | Hideki Sunohara | Process for producing capsule and capsule obtained thereby |
JPH107577A (ja) * | 1996-06-17 | 1998-01-13 | Yakult Honsha Co Ltd | 血糖降下剤 |
ES2258841T3 (es) * | 1998-04-01 | 2006-09-01 | Ganeden Biotech, Inc. | Procedimientos para reducir el colesterol con esporas de bacillus coagulans, sistemas y composiciones asociados. |
EP0956867A1 (de) * | 1998-05-12 | 1999-11-17 | Franz-Peter Dr. Liebel | Verwendung von Flavonoidglykosiden, Gerbstoffen und Mikroorganismen zur Therapie und Prophylaxe des Diabetes mellitus |
US6042823A (en) * | 1998-07-02 | 2000-03-28 | Amano Pharmaceuticals Co., Ltd. | Enzyme composition and use thereof |
US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
US6641808B1 (en) * | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
US6464607B1 (en) * | 1999-12-15 | 2002-10-15 | The Goodyear Tire & Rubber Company | Power transmission belt |
US6486314B1 (en) * | 2000-05-25 | 2002-11-26 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Glucan incorporating 4-, 6-, and 4, 6- linked anhydroglucose units |
US6942857B2 (en) * | 2002-08-09 | 2005-09-13 | Bioneer Corporation | Microorganisms for preventing and/or treating obesity or diabetes mellitus |
-
2000
- 2000-11-30 JP JP2000364295A patent/JP4580542B2/ja not_active Expired - Lifetime
-
2001
- 2001-02-23 CN CN018012868A patent/CN1380902B/zh not_active Expired - Lifetime
- 2001-02-23 AT AT01908427T patent/ATE349511T1/de not_active IP Right Cessation
- 2001-02-23 EP EP01908427A patent/EP1282687B1/de not_active Expired - Lifetime
- 2001-02-23 WO PCT/KR2001/000269 patent/WO2001088095A1/en active IP Right Grant
- 2001-02-23 DE DE60125529T patent/DE60125529T2/de not_active Expired - Lifetime
- 2001-02-23 AU AU36170/01A patent/AU3617001A/en not_active Abandoned
- 2001-05-16 US US09/855,836 patent/US6808703B2/en not_active Expired - Lifetime
-
2003
- 2003-02-03 US US10/356,542 patent/US20030180273A1/en not_active Abandoned
- 2003-02-03 US US10/356,520 patent/US20030180271A1/en not_active Abandoned
-
2004
- 2004-10-25 US US10/971,116 patent/US20050112112A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4580542B2 (ja) | 2010-11-17 |
WO2001088095A1 (en) | 2001-11-22 |
DE60125529D1 (de) | 2007-02-08 |
JP2001321163A (ja) | 2001-11-20 |
EP1282687A1 (de) | 2003-02-12 |
US6808703B2 (en) | 2004-10-26 |
AU3617001A (en) | 2001-11-26 |
EP1282687B1 (de) | 2006-12-27 |
US20030180273A1 (en) | 2003-09-25 |
CN1380902A (zh) | 2002-11-20 |
US20030180271A1 (en) | 2003-09-25 |
CN1380902B (zh) | 2010-10-27 |
US20050112112A1 (en) | 2005-05-26 |
US20020037577A1 (en) | 2002-03-28 |
DE60125529T2 (de) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE349511T1 (de) | Mikroorganismen für die behandlung oder vorbeugung von fettleibigkeit und diabetes mellitus und pharmazeutische zusammensetzungen, die diese enthalten | |
MA33046B1 (fr) | Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations | |
IL107134A0 (en) | Pharmaceutical compositions for the treatment of parkinson's disease | |
BR0109326A (pt) | Inibidores de sglt2 de glucosìdio de o-arila e método | |
BR0112685A (pt) | Composição nutricional | |
MX2010001560A (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv. | |
BR9608041B8 (pt) | Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório. | |
UA89791C2 (ru) | Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта | |
BR0114310A (pt) | Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos | |
UA100008C2 (ru) | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и фармацевтической композицией, которая их содержит | |
BRPI0517701A (pt) | uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus | |
BR0107901A (pt) | Composto, composição farmacêutica, método para o trtamento de enfermidade, para o trtamento e/ou prevenção de condições mediadas por receptores nucleares, e para o tratamento e/ou prevenção de diabetes e/ou obesidade, uso de um composto, e, método para tratar diabetes de tipo i, diabetes de tipo ii, tolerância à gligose prejudicada, resistência à insulina ou obesidade | |
WO2006023342A3 (en) | Synergistic conjugated linoleic acid (cla) and carnitine combination | |
PT1455802E (pt) | Oligossacáridos de quitosano e suas utilizações | |
BR0314335A (pt) | Composto, uso do mesmo, composição farmacêutica, e métodos para o tratamento e/ou prevenção de condições mediadas por receptores nucleares, e de diabetes de tipo i, diabetes de tipo ii, tolerância prejudicada à glicose, resistência à insulina ou obesidade | |
WO2004004636A3 (en) | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis | |
BR0112919A (pt) | Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter | |
GB2456475A (en) | Composition for the treatment of skin conditions | |
MXPA04007183A (es) | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. | |
TW200724147A (en) | Cognitive abilities improving agent | |
SE9901007D0 (sv) | Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence | |
JP4778723B2 (ja) | 抗炎症剤 | |
ATE454397T1 (de) | Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid | |
CA2314817A1 (en) | Synergistic agents for enhancing tissue repair | |
TW200806314A (en) | Immunogenic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |